Demonstrated Solid-State Stability of Parathyroid Hormone PTH(1–34) Coated on a Novel Transdermal Microprojection Delivery System

PurposeThis study assessed conditions necessary for at least a 2-year, ambient temperature storage stability of the peptide parathyroid hormone 1–34, or PTH(1–34), coated on a novel transdermal microprojection delivery system, or ZP-PTH.MethodsLiquid coating characterization of high concentration PTH(1–34) formulations (>20% w/w) was assessed by viscosity and contact angle measurements along with RP-HPLC and SEC-HPLC. Solid-state coating morphology of PTH(1–34) on microprojection arrays was determined by SEM, and stability on storage was assessed after dissolution and testing with stability indicating assays. Internal vapor analysis was performed to detect and quantify volatile organics released by patch components into the headspace inside the final package.ResultsAggregation and oxidation were the primary degradation mechanisms for solid-state PTH(1–34) in this transdermal delivery system. Although these two degradation pathways can be retarded by appropriate stabilizers and use of foil pouch packaging (nitrogen purged and desiccant), the solid-state drug formulation’s compatibility with patch components, particularly the plastic retainer ring, surprisingly dictated PTH(1–34) stability. Internal vapor analysis demonstrated that PTH(1–34) was particularly vulnerable to vapors such as moisture, oxygen, and outgassed formaldehyde, and each of these volatiles played a unique and significant role in PTH(1–34)’s degradation mechanism.ConclusionsIdentifying degradation mechanisms of volatile compounds on solid-state PTH(1–34) peptide stability allowed for the rationale for selection of final formulation, system components and packaging conditions. A >2-yr, ambient temperature storage stability was demonstrated for solid-state drug coated on a novel transdermal microprojection delivery system. This system was successfully tested in a Phase 2 clinical trial for the treatment of post-menopausal women with osteoporosis.

[1]  M. Cormier,et al.  Transdermal Delivery of Antisense Oligonucleotides with Microprojection Patch (macroflux®) Technology , 2001, Pharmaceutical Research.

[2]  G. Dalsky,et al.  Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. , 2005, Archives of internal medicine.

[3]  L. Fraenkel,et al.  Patient treatment preferences for osteoporosis. , 2006, Arthritis and rheumatism.

[4]  A. Frelinger,et al.  Oxidized forms of parathyroid hormone with biological activity. Separation and characterization of hormone forms oxidized at methionine 8 and methionine 18. , 1984, The Journal of biological chemistry.

[5]  S. Boonen,et al.  Teriparatide or alendronate in glucocorticoid-induced osteoporosis. , 2007, The New England journal of medicine.

[6]  R. Borchardt,et al.  Stability of Protein Pharmaceuticals , 1989, Pharmaceutical Research.

[7]  M. Cormier,et al.  Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system. , 2006, Vaccine.

[8]  Dennis M Black,et al.  Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans , 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[9]  L. Fraenkel,et al.  Patient willingness to take teriparatide. , 2007, Patient education and counseling.

[10]  A. Frelinger,et al.  The role of the methionine residues in the structure and function of parathyroid hormone. , 1986, Archives of biochemistry and biophysics.

[11]  J. Zull,et al.  Effect of methionine oxidation and deletion of amino-terminal residues on the conformation of parathyroid hormone. Circular dichroism studies. , 1990, The Journal of biological chemistry.

[12]  M. Staples,et al.  Long-term Stability and in vitro Release of hPTH(1–34) from a Multi-reservoir Array , 2008, Pharmaceutical Research.

[13]  J. Matriano,et al.  Macroflux® Microprojection Array Patch Technology: A New and Efficient Approach for Intracutaneous Immunization , 2004, Pharmaceutical Research.

[14]  Y. Nabuchi,et al.  The Stability and Degradation Pathway of Recombinant Human Parathyroid Hormone: Deamidation of Asparaginyl Residue and Peptide Bond Cleavage at Aspartyl and Asparaginyl Residues , 1997, Pharmaceutical Research.

[15]  J. Finkelstein,et al.  The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. , 2003, The New England journal of medicine.

[16]  Mahmoud Ameri,et al.  Transdermal delivery of desmopressin using a coated microneedle array patch system. , 2004, Journal of controlled release : official journal of the Controlled Release Society.